Clinical trials
Recurrent or Metastatic Cervical Cancer clinical trials
Below are recruiting recurrent or metastatic cervical cancer clinical trials, each written for real people, not researchers. We’re tracking 3,905 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07233473Recruiting
Vaginal gel for preventing repeat urinary tract infections
This trial tests a vaginal gel to see if it can prevent frequent urinary tract infections (UTIs) in women. It may help if you have had at least 4 UTIs in the past year or 2 in the past 6 months.
VilleurbanneAges 18–84 - NCT07250724Recruiting
C. diff Toxin Levels After Antibiotic Treatment
This study looks at levels of C. diff toxins in stool after standard antibiotic treatment. It aims to understand how toxins change during recovery, which may help improve future treatments for C. diff infections.
Atlanta, GeorgiaAges 18 years+ - NCT04645602RecruitingPhase 2
Study of pembrolizumab and lenvatinib for lung papillomas
This early-phase trial tests how well pembrolizumab plus lenvatinib can treat respiratory papillomas that have spread to the lungs. It may help people whose lung disease is caused by human papillomavirus (HPV).
New Haven, ConnecticutAges 18 years+ - NCT06365619RecruitingPhase 2
Immunotherapy before surgery for recurrent melanoma
This trial tests two immunotherapy drugs, ipilimumab and nivolumab, given before surgery for people whose melanoma has come back after previous anti-PD1 treatment. The goal is to see if this combination can shrink the tumor and help prevent future recurrence.
Salt Lake City, UtahAges 18 years+ - NCT07647744RecruitingPhase 1
CD70-Targeted Cell Therapy for Advanced Kidney Cancer
This study tests a new cell-based treatment designed to target kidney cancer cells that have a protein called CD70. The treatment involves collecting your immune cells, modifying them in the lab, and infusing them back to fight the cancer. It's for patients with advanced kidney cancer who have already tried at least one standard immunotherapy.
ShanghaiAges 18–70 - NCT07261826Recruiting
Long-term effects of fecal microbiota transplant
This study looks at how well fecal microbiota transplantation (FMT) works over time and checks its safety. If you have received at least one FMT for a qualifying condition, you may be able to participate.
Shanghai, Shanghai MunicipalityAges 3 years+ - NCT07263906RecruitingPhase 1
LILRA6 car-t therapy for resistant or relapsed aml
This early-phase trial tests a new cell therapy (CAR-T) that targets a protein called LILRA6 on leukemia cells. It's designed for people whose acute myeloid leukemia (AML) has come back or hasn't responded to standard treatments.
Hangzhou, ZhejiangAges 18–75 - NCT07264075RecruitingPhase 3
Ivonescimab with or without ligufalimab vs pembrolizumab for head and neck cancer
This trial tests a new immunotherapy combination (ivonescimab alone or with ligufalimab) against the standard immunotherapy pembrolizumab (Keytruda) for people with head and neck cancer that has come back or spread. It may be an option if you have not had any prior immunotherapy and your tumor is PD-L1 positive.
Le HavreAges 18–80 - NCT07264569RecruitingPhase 1/Phase 2
Testing a new drug for lung cancer that has spread to the brain or spinal fluid
This trial tests a new drug called BioTTT001 for people with non-small cell lung cancer (NSCLC) that has spread to the fluid around the brain or the lining of the brain (leptomeninges). The goal is to see if the drug is safe and can help control the cancer.
Zhengzhou, HenanAges 18–70 - NCT07268053RecruitingEarly Phase 1
B7-H3 drug for recurrent brain tumor or brain metastases
This trial tests a drug called GSK5764227 (a B7-H3 targeted antibody-drug conjugate) in people whose glioblastoma has come back after standard treatment, or who have brain metastases that need surgery. The goal is to see if the drug can help shrink or control the tumor.
Phoenix, ArizonaAges 18 years+ - NCT07280832RecruitingPhase 1/Phase 2
Study of JMT108 for advanced melanoma
This trial tests a new drug, JMT108, for people with advanced melanoma that can't be removed by surgery or has spread. It's for those who have tried other treatments or have no good options left.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07282184RecruitingPhase 1/Phase 2
Liver cancer risk prediction and treatment study
This trial uses a computer model to predict if your liver cancer might come back aggressively after surgery. If you are at high risk, you may receive additional treatment before surgery to lower that risk.
Wuhan, HubeiAges 18–75 - NCT07282262RecruitingPhase 2
Ivosidenib for advanced bile duct cancer with IDH1 mutation
This trial tests the drug Ivosidenib for people with advanced bile duct cancer that has a specific genetic change called an IDH1 mutation. It may be an option if you haven't had chemotherapy yet or if your cancer returned more than 6 months after surgery.
BeijingAges 18–80 - NCT07282912RecruitingPhase 2
Extra treatment for certain digestive cancers with undetectable ctDNA
This trial tests if adding extra local treatments (like surgery or radiation) to usual care can improve outcomes for people with certain advanced digestive cancers that have spread to a limited number of sites. You may be eligible if your cancer has responded well to at least 4 months of therapy and your ctDNA (a sign of cancer in the blood) is undetectable.
New Haven, ConnecticutAges 18–80 - NCT07283822RecruitingPhase 2
Pembrolizumab and Ruxolitinib for Lymphoma
This trial is testing two drugs, pembrolizumab and ruxolitinib, together for people with certain types of lymphoma that have come back or not responded to at least one prior treatment. The goal is to see if this combination can help control the lymphoma.
New York, New YorkAges 18–95 - NCT07284121Recruiting
Patient satisfaction and safety of Atezolizumab in routine care
This study tracks how well Atezolizumab (Tecentriq) works for people with certain lung or liver cancers in everyday medical practice. It helps doctors understand if patients are satisfied with their treatment and how it affects their quality of life.
KremsAges 18 years+ - NCT07288801RecruitingPhase 4
Vitamin D to prevent preeclampsia again in pregnancy
This trial tests whether taking vitamin D can help pregnant women who had preeclampsia before avoid getting it again. It may protect both you and your baby.
Multan, Punjab ProvinceAges 20–45 - NCT07291180Recruiting
Personalized heated chemo for advanced appendix or colon cancer
This study tests a personalized way to deliver heated chemotherapy directly into the belly during surgery for advanced appendix or colorectal cancer that has spread to the lining of the abdomen. The goal is to see if tailoring the chemo drugs to your tumor can improve outcomes.
New Haven, ConnecticutAges 18–81 - NCT07295262RecruitingEarly Phase 1
New imaging to guide liver cancer surgery
This trial tests a new imaging technique that uses a special dye combined with a chemotherapy drug to help surgeons see and remove liver cancer more precisely during surgery. It is for people with a first-time, single liver tumor that is small and can be surgically removed.
Chengdu, SichuanAges 18–75 - NCT07295340Recruiting
New imaging dye test for liver cancer detection
This trial tests a special dye that targets liver cancer cells to help surgeons see tumor edges more clearly during surgery. It may help ensure all cancer is removed in one operation.
Chengdu, SichuanAges 18–80 - NCT07295821RecruitingPhase 2
Osimertinib for stage III lung cancer patients who can't have chemo
This trial tests a targeted therapy pill (osimertinib) combined with radiation for people with a specific type of stage III lung cancer (EGFR mutation-positive) who cannot receive chemotherapy. The goal is to see if this treatment can shrink or control the cancer.
BeijingAges 18 years+ - NCT07298083Recruiting
Identifying markers for MPNST to improve diagnosis and surgery
This trial collects tissue samples from people with MPNST or neurofibroma during surgery to find metabolic markers that could help diagnose MPNST faster and ensure complete removal of tumors.
Houston, TexasAges 1 year+ - NCT07298473Recruiting
Redo ablation for recurrent atrial fibrillation with Sphere-9 catheter
This trial tests a new catheter and system for people who have had one previous ablation for atrial fibrillation but still have symptoms. It aims to see if a repeat procedure can safely and effectively treat recurrent episodes.
Birmingham, AlabamaAges 18 years+ - NCT07300449RecruitingPhase 2
Predicting chemo response in children with hepatoblastoma
This trial tests a new way to see if chemotherapy will work for children with hepatoblastoma, a type of liver cancer. It uses a blood test (ctDNA 5hmc) to help predict treatment success and monitor if the cancer comes back.
Guangzhou, GuangdongAges Up to 18 years
Hear when a new Recurrent or Metastatic Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic cervical cancer?
- Yes. Clin2 currently lists 3,905 recruiting recurrent or metastatic cervical cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic cervical cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic cervical cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.